PharmaMar , según los Analistas de Edison Investment Research , Tan solo Contando con Yondelis en Europa vale más que el Valor actual en Bolsa .
Top-line data from the Zepsyre (aka lurbinectedin and PM1183) Phase III in Platinum-Resistant Ovarian Cancer is due by early 2018.
A Second Pivotal Study is evaluating Zepsyre ( Lurbinectedin ) in combination with Doxorubicin in patients with Small Cell Lung Cancer ( SCLC ).
A Phase III in BRCA2-Mutated Breast Cancer is Planned, and Pivotal studies in Endometrial Cancer have been flagged following a 44% response rate in Phase I.
*********************
Del último informe de Edison ... Eliminaramos Aplidin ... Nos Quedaría un Precio Objetivo de 7,38 euros :